We want to understand why some patients respond better to cancer therapies than others.
At the present time, we are experiencing that many new drugs and methods are flooding the market. The result is a wide range of possible combinations. We want to identify the best combination for each individual – but traditional methods of examining patients are no longer sufficient for this.
We would like to demonstrate reliable solutions for groups of patients that are as clearly defined as possible in a respective situation in order to overcome therapy resistance.
The biggest obstacle is understanding the complexity of the signalling pathways that lead to therapy resistance. We will use new, computer-aided methods, such as artificial intelligence (AI), for this difficult question.
We act according to the principle: “Try harder”. Unfortunately, in medicine we are accustomed to having to pursue many different approaches until one finally works. But basically, failure is an incentive.
When I look into the eyes of patients who are alive because we were able to leave the beaten track together with them and new therapeutic approaches were successful, then that is the greatest success for me.